home / stock / ttph / ttph quote
Last: | $2.20 |
---|---|
Change Percent: | -3.51% |
Open: | $2.24 |
Close: | $2.20 |
High: | $2.27 |
Low: | $2.18 |
Volume: | 279,969 |
Last Trade Date Time: | 07/28/2020 04:56:12 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.2 | $2.24 | $2.2 | $2.27 | $2.18 | 279,969 | 07-28-2020 |
$2.28 | $2.38 | $2.28 | $2.44 | $2.1703 | 501,384 | 07-27-2020 |
$2.38 | $2.28 | $2.38 | $2.4 | $2.27 | 373,882 | 07-24-2020 |
$2.28 | $2.38 | $2.28 | $2.4217 | $2.23 | 273,150 | 07-23-2020 |
$2.4 | $2.45 | $2.4 | $2.48 | $2.37 | 95,969 | 07-22-2020 |
$2.47 | $2.5 | $2.47 | $2.55 | $2.42 | 119,349 | 07-21-2020 |
$2.5199 | $2.5 | $2.5199 | $2.5228 | $2.45 | 25,636 | 07-20-2020 |
$2.55 | $2.51 | $2.55 | $2.56 | $2.5 | 64,509 | 07-17-2020 |
$2.51 | $2.43 | $2.51 | $2.54 | $2.41 | 58,530 | 07-16-2020 |
$2.46 | $2.4 | $2.46 | $2.49 | $2.38 | 62,169 | 07-15-2020 |
$2.39 | $2.36 | $2.39 | $2.45 | $2.36 | 98,530 | 07-14-2020 |
$2.405 | $2.47 | $2.405 | $2.47 | $2.3474 | 107,996 | 07-13-2020 |
$2.43 | $2.46 | $2.43 | $2.48 | $2.4201 | 54,709 | 07-10-2020 |
$2.48 | $2.52 | $2.48 | $2.59 | $2.42 | 123,205 | 07-09-2020 |
$2.53 | $2.6 | $2.53 | $2.6 | $2.52 | 40,391 | 07-08-2020 |
$2.58 | $2.41 | $2.58 | $2.66 | $2.4 | 254,419 | 07-07-2020 |
$2.44 | $2.46 | $2.44 | $2.498 | $2.4101 | 129,699 | 07-06-2020 |
$2.46 | $2.54 | $2.46 | $2.56 | $2.4 | 228,151 | 07-03-2020 |
$2.46 | $2.54 | $2.46 | $2.56 | $2.4 | 227,851 | 07-02-2020 |
$2.56 | $2.51 | $2.56 | $2.56 | $2.495 | 70,290 | 07-01-2020 |
News, Short Squeeze, Breakout and More Instantly...
Tetraphase Pharmaceuticals Inc. Company Name:
TTPH Stock Symbol:
NASDAQ Market:
Tetraphase Pharmaceuticals Inc. Website:
SAN DIEGO, California and WATERTOWN, Massachusetts, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening disease...
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights Combined company will offer two innovative therapies to treat patients suffering from life-threatening diseases SAN DIEGO, Ca...
Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM (eravacycline for injection) to treat serious and life-threatening infections, today announced that on June 19, 2020, its Board of Directors received an uns...